hepatitis-b

Stat

GSK Drug Achieves Functional Cure in 19-20% of Hepatitis B Patients

Two Phase 3 trials showed GSK's bepirovirsen produced functional cures in nearly one-fifth of chronic hepatitis B patients. Current nucleoside analogue treatments reach functional cures in only 1-3% of cases. The company has submitted the drug for regulatory approval.

2 sources